TCM
TGTX icon

Teza Capital Management’s TG Therapeutics TGTX Stock Holding History

Teza Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,506
Closed -$526K – 702
2024
Q3 		$526K Buy
+22,506
New +$492K 0.06% 364
2024
Q1 		– Sell
-22,595
Closed -$386K – 743
2023
Q4 		$386K Buy
+22,595
New +$263K 0.06% 358
2017
Q1 		– Sell
-10,278
Closed -$48K – 584
2016
Q4 		$48K Buy
+10,278
New +$60.3K 0.07% 222

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Teza Capital Management's TGTX Position: Q4 2024 in Review

Teza Capital Management sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 22,506 shares — an estimated $526K sold.

Teza Capital Management first reported a position in TGTX in Q4 2016 and held it in 3 quarters. The position peaked at $526K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Teza Capital Management reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Teza Capital Management sold 22,506 TG Therapeutics shares in Q4 2024, an estimated $526K.
  • Teza Capital Management first reported a position in TG Therapeutics in Q4 2016 and held it in 3 quarters.
  • Teza Capital Management's TG Therapeutics position peaked at $526K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Teza Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.